In Vivo Pharmacodynamic Evaluation of Omadacycline (PTK 0796) against Streptococcus pneumoniae in the Murine Pneumonia Model.

In vivo Pharmacodynamic Evaluation of Omadacycline (PTK 0796) against Staphylococcus aureus (SA) in the Murine Thigh Infection Model

In vitro and in vivo antibacterial activities of omadacycline, a novel aminomethylcycline.

Omadacycline is the first intravenous and oral 9-aminomethylcycline in clinical development for use against multiple infectious diseases including acute bacterial skin and skin structure infections (ABSSSI), community-acquired bacterial pneumonia (CABP), and urinary tract infections (UTI). The comparative in vitro activity of omadacycline was determined against a broad panel of Gram-positive cl...

BAY 73-7388, a novel aminomethylcycline, is highly active in vivo in a murine model of pneumococcal pneumonia

Objectives: BAY 73-7388 is the first antibiotic compound selected from the novel class, the aminomethylcyclines. BAY 73-7388 is under development for the treatment of severe bacterial infections including those caused by strains resistant to current classes of antibiotics.The efficacy of BAY 73-7388 was compared with that of vancomycin (VAN) and linezolid (LZD) in a mouse model of pneumococcal ...

Activity of omadacycline tested against Streptococcus pneumoniae from a global surveillance program (2014).

The activity of omadacycline and comparators when tested against a subset of Streptococcus pneumoniae from US and European regions of a 2014 global surveillance program (304 isolates) are reported. These MIC results were compared to those obtained when testing S. pneumoniae from 2010 surveillance (1,834 isolates). The omadacycline MIC50/90 for S. pneumoniae (2014) was 0.06/0.06μg/mL, similar to...

In vitro Antibacterial Evaluation of Newly Synthesized Heterocyclic Compounds Against Streptococcus Pneumoniae

In recent years, the spread of drug-resistant strains of Streptococcus pneumoniae, as the most common causes of bacterial respiratory infections, threatens public health. Therefore, the use of new antimicrobial medicines to inhibit this pathogen is an urgent demand. In this research project, the inhibitory effects of thirty recently synthesized compounds including thiazole, thiazolidine, imidaz...